Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03217175 · ClinicalTrials.gov registry record · NA
Efficacy of Glucagon In the Prevention of Hypoglycemia During Mild Exercise
A NA study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT03217175: Clinical Trial NA study, sponsored by Massachusetts General Hospital.
NCT03217175 is a NA study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03217175, a NA study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
The study will consist of two study arms. Each arm will include a 24-96 hour outpatient run-in period prior to their exercise visit wearing the bi-hormonal bionic pancreas. In random order subjects will then complete two approximately 5-hour exercise visits, one wearing the bi-hormonal bionic pancreas and one wearing the insulin-only bionic pancreas.
Interventions
- DRUG Placebo
- DRUG Glucagon
- DEVICE Bihormonal Bionic Pancreas
- DEVICE Insulin Only Bionic Pancreas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2017-08-18 |
| Est. Completion | 2018-03-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03217175
The ClinicalTrials.gov registry entry for NCT03217175 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03217175 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03217175 about?
NCT03217175 is a clinical study titled "Efficacy of Glucagon In the Prevention of Hypoglycemia During Mild Exercise". The study will consist of two study arms. Each arm will include a 24-96 hour outpatient run-in period prior to their exercise visit wearing the bi-hormonal bionic pancreas. In random order subjects will then complete two approximately 5-hour exercise visits, one wearing the bi-hormonal bionic pancre...
What is the current status of trial NCT03217175?
This trial is currently terminated. It is a NA study. The enrollment target is 22 participants. The study started on 2017-08-18. Estimated completion is 2018-03-09.
What interventions are being tested in trial NCT03217175?
The interventions under investigation include: Placebo (DRUG), Glucagon (DRUG), Bihormonal Bionic Pancreas (DEVICE), Insulin Only Bionic Pancreas (DEVICE).
Who is sponsoring clinical trial NCT03217175?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.